What is the dosing schedule, indications, contraindications, and monitoring for Vivitrol (extended‑release naltrexone) injection?

Vivitrol (Extended-Release Naltrexone) Injection

Vivitrol is administered as a 380 mg deep intramuscular gluteal injection every 4 weeks (monthly), alternating buttocks, and must be prepared and administered by a healthcare provider using the customized needles provided in the carton. 1

Indications

Vivitrol is FDA-approved for two specific conditions 1:

1. Alcohol Dependence: For patients who can abstain from alcohol in an outpatient setting prior to initiation and are not actively drinking at the time of first administration

2. Opioid Dependence: For prevention of relapse to opioid dependence following opioid detoxification

Treatment must be part of a comprehensive management program that includes psychosocial support. 1

Dosing Schedule

• Standard dose: 380 mg intramuscularly every 4 weeks (monthly) 1
• Route: Deep intramuscular gluteal injection ONLY—must alternate buttocks with each injection
• Administration: Must be prepared and administered by a healthcare provider using the specific needles provided (1.5-inch or 2-inch depending on body habitus) 1
• Missed doses: Administer the next dose as soon as possible 1
• No oral pretreatment required: Pretreatment with oral naltrexone is not necessary before starting Vivitrol 1

Critical Body Habitus Considerations

Assess body habitus before each injection 1:

• Larger subcutaneous tissue: Use the 2-inch needle to ensure intramuscular delivery
• Very lean patients: Use the 1.5-inch needle to avoid periosteal contact
• Average body habitus: Either needle length is appropriate
• If adequate intramuscular injection cannot be achieved: Consider alternate treatment

Contraindications

Vivitrol is absolutely contraindicated in 1:

1. Patients currently receiving opioid analgesics
2. Patients with current physiologic opioid dependence
3. Patients in acute opioid withdrawal
4. Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids
5. Patients with previous hypersensitivity to naltrexone, polylactide-co-glycolide (PLG), carboxymethylcellulose, or any diluent components

Pre-Treatment Requirements

For opioid-dependent patients, an opioid-free duration of minimum 7-10 days is mandatory before initiating Vivitrol to avoid precipitating severe opioid withdrawal that may require hospitalization. 1 This applies to both patients being treated for opioid dependence AND those being treated for alcohol dependence who may be using opioids 2.

Verification Steps Before First Dose:

• Confirm patient has been opioid-free for 7-10 days minimum
• Verify negative urine drug screen for opioids
• Consider naloxone challenge test if opioid use history is uncertain
• Ensure patient is not actively drinking (for alcohol dependence indication)

Monitoring Requirements

Hepatic Monitoring

Obtain liver function tests at baseline and every 3-6 months during treatment 2. Naltrexone has been associated with hepatic injury at supratherapeutic doses, and cases of hepatitis and clinically significant liver dysfunction have been observed 1.

Discontinue Vivitrol immediately if signs or symptoms of acute hepatitis develop 1.

Mental Health Monitoring

Monitor all patients for development of depression or suicidal thinking throughout treatment 1. This is particularly important given the high comorbidity of mood disorders in patients with substance use disorders 2.

Overdose Risk Assessment

At each injection visit, assess overdose risk and ensure patient/caregiver access to an opioid overdose reversal agent (naloxone or nalmefene) 1. This is critical because:

• Patients have reduced opioid tolerance after Vivitrol treatment
• Risk is highest at the end of the dosing interval (near end of month)
• Risk increases after a missed dose or treatment discontinuation
• Attempts to overcome the opioid blockade can lead to fatal overdose 1

Injection Site Monitoring

Inspect injection sites at each visit. Some injection site reactions can be severe and may require surgical intervention 1.

Additional Monitoring

• Opioid craving scores: Track throughout treatment (research shows significant reduction with Vivitrol) 3
• Substance use: Urine drug screens and self-reported use
• Treatment retention: Document adherence to monthly injections

Important Clinical Considerations

Efficacy Data

In a pivotal Russian trial, patients receiving Vivitrol achieved a median of 90% confirmed abstinence weeks compared to 35% with placebo, with significantly longer retention (>168 days vs 96 days) 3. However, real-world adherence is challenging—only 44% of patients complete all scheduled injections in typical practice 4.

Induction Success Rates

Induction success is significantly higher (85%) in patients already detoxified from opioids compared to those requiring detoxification first (62.6%) 4. This underscores the importance of successful detoxification before attempting Vivitrol initiation.

Pain Management Concerns

Vivitrol blocks the analgesic effects of opioid pain medications 2. In emergency situations requiring pain management:

• Consider regional analgesia
• Use non-opioid analgesics
• Higher doses of opioids may be needed to overcome blockade, increasing overdose risk 1

Rare but Serious Adverse Events

• Eosinophilic pneumonia: If patients develop dyspnea and hypoxemia, consider this diagnosis, especially if not responding to antibiotics 1
• Anaphylaxis: Cases of urticaria, angioedema, and anaphylaxis have been reported 1

Common Adverse Events (≥5% and twice placebo rate)

Nausea, vomiting, injection site reactions (induration, pruritus, nodules, swelling), muscle cramps, dizziness/syncope, somnolence/sedation, anorexia, decreased appetite 1

Key Clinical Pitfalls to Avoid

1. Never administer to patients still using opioids—this will precipitate severe withdrawal
2. Never use non-customized needles—the provided needles are specifically designed for proper administration
3. Never inject subcutaneously or intravenously—must be deep intramuscular gluteal only
4. Do not assume 7 days opioid-free is sufficient—7-10 days minimum is required, and some patients may need longer
5. Do not forget overdose prevention counseling—patients are at high risk after discontinuation or missed doses